HealthCert Blog

The Australasian College of Dermatologists has published a position statement on isotretinoin for the treatment of acne. The statement provides evidence-based information about isotretinoin for the treatment of acne in the Australian clinical and regulatory context, and in particular, use in women of childbearing potential, other contraindications, precautions, dosage, adverse effects and mental health.

Isotretinoin is an oral retinoid indicated for the treatment of severe, persistent or scarring acne. It has been in clinical use for over 30 years and is accepted as the most effective treatment for severe acne, with most patients achieving long term remission.

Isotretinoin can only be prescribed in Australia by specialist dermatologists and physicians. Patients receiving isotretinoin may also be under the care of general practitioners or other healthcare professionals for related or unrelated conditions. Isotretinoin is listed on the PBS for the treatment of severe cystic acne that does not respond to standard therapies. Dermatologists can prescribe isotretinoin for other indications but these are not eligible for PBS reimbursement.

There is currently no standard grading system for acne. When treating acne dermatologists consider types of acne lesions, disease severity, anatomical sites and scarring to guide disease management planning and evaluate treatment response.

Download the statement here.

Read more recent research on acne.

Source: Australasian College of Dermatologists position statement on isotretinoin for the treatment of acne. Dermatology Practice Review. Issue 7 – 2018. Page 1.

Interested in General Dermatology?